

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Dalit BARKAN et al

Art Unit: 1642

Application No.: 09/403,897

Conf. No.7830

Examiner: K. Canella

Filed: February 22, 2000

Washington, D.C.

For: LEPTIN AS AN INHIBITOR OF TUMOR CELL PROLIFERATION

Atty.'s Docket: BARKAN=2

Date: December 29, 2004

THE COMMISSIONER OF PATENTS
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202



Sir:

Transmitted herewith is a [XX] Amendment []
in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[] No additional fee is required.

[XX] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 18	MINUS	** 27	0
INDEP.	* 2	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 25	\$
x 100	\$
+ 180	\$
ADDITIONAL FEE TOTAL	
	\$

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 50	\$
x 200	\$
+ 360	\$
TOTAL	
	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
Response Filed Within
[] First - \$ 60.00
[] Second - \$ 225.00
[] Third - \$ 510.00
[] Fourth - \$ 795.00
Month After Time Period Set

Other Than Small Entity
Response Filed Within
[] First - \$ 120.00
[XX] Second - \$ 450.00
[] Third - \$ 1,020.00
[] Fourth - \$ 1,590.00
Month After Time Period Set

[] Less fees (\$) already paid for month(s) extension of time on .

[] Please charge my Deposit Account No. 02-4035 in the amount of \$.

[XX] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$450.00 .

[] A check in the amount of \$ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

12/30/2004 YPOLITE1 00000117 10403897

01 FC:1252

450.00 0P

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By:
Roger L. Browdy
Registration No. 25,618



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: BARKAN=2

In re Application of:)	Art Unit: 1642
)	
Dalit BARKAN et al)	Examiner: K. Canella
)	
Appln. No.: 09/403,897)	Confirmation No. 7830
)	
Filed: February 22, 2000)	Washington, D.C.
)	
For: LEPTIN AS AN INHIBITOR OF)	December 29, 2004
TUMOR CELL PROLIFERATION)	

AMENDMENT

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window Amendment
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

In response to the Office Action of October 29,
2003, please amend as follows:

Amendments to the Claims are reflected in the
listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 9 of this paper.